Moderna (MRNA.US) started the week with an exceptionally dismal session, with a stock declining around 20%. Investors are selling off shares of the mRNA vaccine producer following the downward revision of its 2025 sales forecast by a full billion dollars.
Moderna expects revenue of between $1.5 billion and $2.5 billion in 2025, on average 30% below analysts' consensus. To improve profitability, CEO Stéphane Bancel announced a reduction in operational costs by $1 billion in 2025 and an additional $500 million in savings in 2026
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
The company’s forecasts have raised concerns about its profitability and competitiveness in the tight pharmaceutical market. Disappointing projections are primarily driven by the weak market adoption of its latest RSV vaccine and a continued decline in demand for COVID-19 vaccines. There is also little enthusiasm for the portfolio of currently developed projects, such as the CMV vaccine, which has so far failed to achieve planned efficacy in a clinical trial ongoing since 2021, or the combined COVID-19 and flu vaccine, which is still awaiting approval from the U.S. Food and Drug Administration (FDA).
MRNA.US (W1)
Although Moderna aligns with the overall downward trend observed among other biotech companies known from the pandemic era (e.g., Pfizer, marked in gray), its shares are losing value at an exceptionally fast pace. In 2024, the company’s shares lost about 60%, and an RSI below 30 indicates oversold conditions.
Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
